Sociedad Americana de Hirudoterapia

Amt für Gesundheit — Fürstentum Liechtenstein

Liechtenstein AG · Liechtenstein · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Liechtenstein's Office of Public Health — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under harmonised Swiss / EEA pharmaceutical and medical device frameworks as appropriate.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Liechtenstein
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Liechtenstein Heilmittelgesetz (HMG) — adopting most Swissmedic decisions under the customs union with Switzerland
  • EEA / EU pharmacovigilance reporting arrangements via the EEA Joint Committee
  • EU MDR 2017/745 (applied via EEA mechanism)

Prescriber Requirements

  • Liechtenstein Ärztekammer–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Dual recognition: Swissmedic-authorised products are typically marketable in Liechtenstein under the Swiss-Liechtenstein customs union; German-language labelling. Standard cold-chain conditions.

Import/Export Rules

Liechtenstein Amt für Lebensmittelkontrolle und Veterinärwesen clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Liechtensteinische Krankenversicherung (LAK / OKP) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed under the basic insurance.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; Liechtenstein's regulatory environment is uniquely dual — sharing Swissmedic authorisation under the Swiss-Liechtenstein customs union while also being an EEA member that applies EU pharmaceutical law via the EEA Joint Committee; whether this dual regime captures live-organism medical devices in a distinct way has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.